Washington University in St. Louis School of Medicine-ko ikertzaileekin lankidetzan egindako argitalpenak (56)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  3. Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

    Blood

  4. Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 20, Núm. 18, pp. 1221-1235

2023

  1. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.

    New England Journal of Medicine, Vol. 388, Núm. 11, pp. 1002-1014

2022

  1. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)

    Nature Medicine

  2. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    Leukemia, Vol. 36, Núm. 5, pp. 1371-1376

  3. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

    Journal for immunotherapy of cancer, Vol. 10, Núm. 8

  4. Randomised controlled trial of a prognostic assessment and management pathway to reduce the length of hospital stay in normotensive patients with acute pulmonary embolism

    The European respiratory journal, Vol. 59, Núm. 2

  5. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

    Nature Medicine, Vol. 28, Núm. 3, pp. 557-567

2021

  1. Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation: A Randomized Clinical Trial

    JAMA - Journal of the American Medical Association, Vol. 326, Núm. 13, pp. 1277-1285

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  3. Inner ear drug delivery through a cochlear implant: Pharmacokinetics in a Macaque experimental model

    Hearing Research, Vol. 404

  4. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

    The Lancet Diabetes and Endocrinology, Vol. 9, Núm. 8, pp. 491-501

2020

  1. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

    Nature Medicine, Vol. 26, Núm. 6, pp. 878-885

  2. First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma

    Clinical Cancer Research, Vol. 26, Núm. 10, pp. 2308-2317

  3. Key components of a hepatobiliary surgery curriculum for general surgery residents: results of the FULCRUM International Delphi consensus

    HPB, Vol. 22, Núm. 10, pp. 1429-1441

  4. Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Genetic variation across RNA metabolism and cell death gene networks is implicated in the semantic variant of primary progressive aphasia

    Scientific Reports, Vol. 9, Núm. 1

  2. Hospital volume and outcomes for acute pulmonary embolism: Multinational population based cohort study

    The BMJ, Vol. 366